<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003753</url>
  </required_header>
  <id_info>
    <org_study_id>98-072</org_study_id>
    <secondary_id>CDR0000066876</secondary_id>
    <secondary_id>MSKCC-98072A(9)</secondary_id>
    <secondary_id>NCI-H99-0024</secondary_id>
    <nct_id>NCT00003753</nct_id>
  </id_info>
  <brief_title>Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer</brief_title>
  <official_title>A Phase I-II Study of Hepatic Arterial Therapy Via Pump (Protocol D97-063) With Floxuridine (FUDR) and Dexamethasone (DEX) in Combination With Intravenous Irinotecan as Adjuvant Treatment After Resection of Hepatic Metastases From Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as floxuridine, dexamethasone, and irinotecan,&#xD;
      use different ways to stop tumor cells from dividing so they stop growing or die. Hepatic&#xD;
      arterial infusion uses a catheter to deliver chemotherapy directly to the liver. Combining&#xD;
      more than one drug and giving them in different ways may kill any tumor cells remaining after&#xD;
      surgery.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of irinotecan combined with hepatic&#xD;
      arterial infusion with floxuridine and dexamethasone after surgery in treating patients who&#xD;
      have liver metastases from colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of hepatic arterial infusion of floxuridine&#xD;
           (FUDR) and dexamethasone given via an implanted pump in combination with weekly&#xD;
           intravenous irinotecan as adjuvant treatment after resection of hepatic metastases in&#xD;
           patients with hepatic metastases from colorectal cancer. (The MTDs of irinotecan and&#xD;
           floxuridine have been reached as of 10/15/03; phase I closed to accrual as of 10/15/03.)&#xD;
&#xD;
        -  Determine the efficacy of this combination chemotherapy after liver resection, in terms&#xD;
           of 2-year survival and 2-year recurrence rates, in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetic effects of intrahepatic FUDR and liver resection on the&#xD;
           metabolism of irinotecan to its active metabolite, SN-38 in these patients.&#xD;
&#xD;
        -  Determine the safety and efficacy of the pump used in delivering intra-arterial&#xD;
           chemotherapy to the liver in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation* study of floxuridine and irinotecan.&#xD;
&#xD;
      Patients undergo hepatic resection and pump placement into the abdomen. About 4 weeks after&#xD;
      surgery, patients receive irinotecan IV over 30 minutes on days 1 and 15. Patients also&#xD;
      receive floxuridine and dexamethasone intra-arterially via an implanted pump continuously on&#xD;
      days 1-14. Treatment repeats every 28 days for 6 courses in the absence of unacceptable&#xD;
      toxicity or disease progression.&#xD;
&#xD;
      Sequential dose escalation of irinotecan is followed by sequential dose escalation of&#xD;
      floxuridine. Cohorts of 3-6 patients receive escalating doses of irinotecan and floxuridine&#xD;
      until the maximum tolerated doses (MTDs) are determined. The MTD* (phase II dose) is defined&#xD;
      as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      NOTE: *The MTDs of irinotecan and floxuridine have been reached as of 10/15/03; phase I&#xD;
      closed to accrual as of 10/15/03&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 4 months for 2-4 years, and then&#xD;
      every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 2-24 patients will be accrued for the phase I portion of this&#xD;
      study within 1 year (phase I closed to accrual as of 10/15/03). A total of 50 additional&#xD;
      patients will be accrued for this study at the phase II dose level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>floxuridine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed colorectal adenocarcinoma&#xD;
&#xD;
          -  Primary colorectal tumor must have been previously resected&#xD;
&#xD;
          -  Potentially completely resectable hepatic metastases (or removable by cryoresection)&#xD;
             without current evidence of other metastatic disease&#xD;
&#xD;
          -  No extrahepatic sites of disease&#xD;
&#xD;
          -  No ascites or hepatic encephalopathy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to the liver&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy to the pelvis&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy E. Kemeny, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>liver metastases</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

